# Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy

> **NCT05514340** · PHASE2 · RECRUITING · sponsor: **Pharmazz, Inc.** · enrollment: 40 (estimated)

## Conditions studied

- Hypoxic-Ischemic Encephalopathy
- Neonatal Asphyxia
- Neonatal Encephalopathy

## Interventions

- **DRUG:** Normal Saline along with standard treatment
- **DRUG:** Sovateltide along with standard treatment

## Key facts

- **NCT ID:** NCT05514340
- **Lead sponsor:** Pharmazz, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-06
- **Primary completion:** 2026-11
- **Final completion:** 2026-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05514340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05514340, "Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05514340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*